Lamotrigine

Lamotrigine

Drug monograph · NCLEX study reference
Trade names	Lamictal
Therapeutic class	Anticonvulsant, mood stabilizer
Pharmacologic class	Sodium channel blocker
Onset / peak / duration	Effect after slow titration over weeks.
Half-life / level	Half-life about 25 hours (varies with interacting drugs); level not routine.
Routes	PO (oral)
High-alert (ISMP)	No
Black box warning	Yes (see Safety)
Antidote / reversal	None; discontinue immediately for serious rash.
Pregnancy / lactation	Used when needed with level monitoring.

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Lamotrigine (brand name Lamictal) — Anticonvulsant, mood stabilizer; Sodium channel blocker.

Identification

• Therapeutic class: Anticonvulsant, mood stabilizer.
• Pharmacologic class: Sodium channel blocker.

Pharmacology

• Mechanism of action: Stabilizes membranes and reduces glutamate release.
• Onset / peak / duration: Effect after slow titration over weeks.
• Half-life / therapeutic level: Half-life about 25 hours (varies with interacting drugs); level not routine.

Clinical use

• Indications: Focal and tonic-clonic seizures, bipolar maintenance.
• Usual dose, route, frequency: Slowly titrated PO; ODT available.
• Maximum dose / adjustments: Titrate very slowly; reduce starting dose and titrate even slower with valproate.

Safety

• Contraindications: Hypersensitivity.
• Black box warning: Serious, potentially life-threatening rashes including Stevens-Johnson syndrome, more likely with rapid titration or with valproate.
• Interactions: Valproate raises levels (rash risk), carbamazepine and oral contraceptives lower levels.
• Pregnancy / lactation: Used when needed with level monitoring.
• High-alert: No.

Adverse effects

• Common side effects: Dizziness, headache, nausea, mild rash.
• Serious effects to report: Any spreading rash, blistering, mucosal involvement, fever.
• Antidote / reversal: None; discontinue immediately for serious rash.

Nursing process

• Assessment before administration: Skin baseline, concurrent valproate, seizure or mood baseline.
• Interventions during therapy: Follow the titration schedule exactly; stop for any significant rash.
• Monitor: Skin, seizure or mood control.
• Evaluation / expected outcome: Seizure or mood stability.

Patient teaching

• Patient teaching: Report any rash at once; never speed up titration.
• Notify provider if: Rash, blisters, mouth sores, fever.
• Administration tips: Slow titration; ODT dissolves on tongue.